Resultados de la búsqueda 1791-1800 of 19575 for WHO
... who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places ...
... who did not have cancer. The increased risk of HF is observed as early as one year from diagnosis of cancer and overall, 7% of patients develop CHF (median ...
... who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL. EF-41/KEYNOTE D58: Phase 3 Study ...
The purpose of this study is to test whether a short course of aspirin can change the markers of inflammation in patients who have a benign finding within ...
Mayo Clinic; 2019. Ebola virus disease. World Health Organization. https://www.who.int/en/news-room/fact-sheets/detail/ebola-virus-disease. Accessed March 17, ...
For patients who consented, patient clinical therapy response data may be correlated with preclinical response data in cell lines and PDX models. ONC201 in ...
The purpose of this study is to examine the microbiome and immune function in patients with active lymphoma, and in patients with a history of lymphoma who are ...
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro-Oncology. 2021. doi:10.1093/neuonc/noab120. Relacionado.
... who have failed 1-2 prior lines of therapy. The primary objectives are to determine the maximum tolerated dose (MTD) or highest protocol-defined dose (HPDD); ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?